Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care.
Switching from any statin to another non-equipotent lipid lowering treatment (LLT) may cause a low-density lipoprotein cholesterol increase and has been associated with a higher probability of negative cardiovascular outcomes. The aim of the study was to assess the impact of switching from rosuvastatin to any other LLT on clinical outcomes in primary care.



This was a retrospective analysis based on data from IMS Health Longitudinal Patient Database, which is a general practice database including information of more than 1.0 million patients representative of the Italian population by age, and medical conditions. Patients that started on rosuvastatin (10-40 mg/day) between January 2011 and December 2013 were considered. The date of the first prescription was defined as the index date (ID). The observation period lasted from the ID to September 2015 or until LLT discontinuation, or the occurrence of an acute myocardial infarction (AMI), or death.



The primary end point of the study was the occurrence of an AMI during the observation period. The final study population included 10,368 patients. During the observation period, 2452 (23.6%) patients were switched from rosuvastatin to another LLT. The majority of patients (55.6%) were switched to atorvastatin, followed by simvastatin (24.9%), simvastatin/ezetimibe combination (10.0%) and other statins (9.5%). Female gender (HR, hazard ratio, 1.10, 95% CI, confidence interval, 1.02-1.19, p = 0.04) and the presence of chronic kidney disease (HR 1.47, 95% CI 1.16-1.86, p = 0.05) were associated with a higher probability of switch. During the observation period, 113 patients experienced an AMI (incidence of 6.7 AMI/1000 patient-years). Multivariate analysis with Cox proportional hazards method, including switching as a time-dependent covariate, demonstrated that changing from rosuvastatin to another LLT was an independent predictor of AMI (HR 2.2, 95% CI 1.4-3.5, p = 0.001).



We conclude that switching from rosuvastatin to another non-equipotent LLT may impart an increased risk of AMI and should be avoided.



AstraZeneca SpA.
Cardiology Division, S. Filippo Neri Hospital, ASL Roma 1, Rome, Italy.
Furio
F
Colivicchi
Cardiology Division, Garibaldi Nesima Hospital, Catania, Italy.
Michele Massimo
MM
Gulizia
AstraZeneca S.p.A., Milan, Italy.
Laura
L
Franzini
Internal Medicine Division, S. Filippo Neri Hospital, ASL Roma 1, Rome, Italy.
Giuseppe
G
Imperoli
Cardiology Division, S. Filippo Neri Hospital, ASL Roma 1, Rome, Italy.
Lorenzo
L
Castello
Cardiology Division, S. Filippo Neri Hospital, ASL Roma 1, Rome, Italy.
Alessandro
A
Aiello
IMS Health Information Solutions Italy S.r.l., Milan, Italy. cripellino@it.imshealth.com.
Claudio
C
Ripellino
IMS Health Information Solutions Italy S.r.l., Milan, Italy.
Nazarena
N
Cataldo
D000368:Aged; D008078:Cholesterol, LDL / Q000097:blood; D057915:Drug Substitution / Q000009:adverse effects / Q000379:methods; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D015994:Incidence; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000517:prevention & control; D011320:Primary Health Care / Q000379:methods; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D000068718:Rosuvastatin Calcium / Q000008:administration & dosage / Q000009:adverse effects
D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000068718:Rosuvastatin Calcium
AMI; Acute myocardial infarction; Cox; Endocrinology; Hazard; Incidence; Lipid lowering; Rosuvastatin; Statin; Switch
Stroke. 2007 Oct;38(10):2652-7
17761916
Eur Heart J. 2011 Jul;32(14):1769-818
21712404
Lancet Diabetes Endocrinol. 2015 Mar;3(3):181-90
25660356
Lancet. 2010 Nov 13;376(9753):1670-81
21067804
Lancet. 2007 Dec 1;370(9602):1829-39
18061058
Am J Manag Care. 2007 Jun;13 Suppl 3:S80-5
17596116
Lancet. 2007 Jan 6;369(9555):27
17208636
Clin Interv Aging. 2013;8:47-59
23355775
J Public Health Med. 2003 Sep;25(3):254-7
14575204
Cerebrovasc Dis. 2003;16(4):410-7
13130183
Int J Clin Pract. 2010 Aug;64(9):1235-8
20653799
Cochrane Database Syst Rev. 2014 Nov 21;(11):CD010254
25415541
Ann Med. 2009;41(4):242-56
19191052
Am J Cardiol. 2003 Jul 15;92(2):152-60
12860216
J Public Health Med. 1999 Sep;21(3):299-304
10528957
J Hypertens. 2010 Jun;28(6):1134-40
20486280
N Engl J Med. 2015 Jun 18;372(25):2387-97
26039521
Int J Cardiol. 2011 Oct 6;152(1):56-60
20674999
Lancet. 1998 Dec 5;352(9143):1830-1
9851392
Eur Heart J. 2012 Oct;33(20):2551-67
22922414
Eur J Prev Cardiol. 2016 Jul;23(11):NP1-NP96
27353126
Lancet. 2005 Oct 8;366(9493):1267-78
16214597
Clinicoecon Outcomes Res. 2015 Nov 27;7:555-65
26664148
Curr Med Res Opin. 2016 Sep;32(9):1493-502
27215310